Yu Y - Search Results

1

Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.

Ren W, Ju X, Gong M, Lan J, Yu Y, Long Q, Kenney DJ, O'Connell AK, Zhang Y, Zhong J, Zhong G, Douam F, Wang X, Huang A, Zhang R, Ding Q. Ren W, et al. Among authors: yu y. mBio. 2022 Apr 26;13(2):e0009922. doi: 10.1128/mbio.00099-22. Epub 2022 Mar 10. mBio. 2022. PMID: 35266815 Free PMC article.

2

Molecular determinants for regulation of G3BP1/2 phase separation by the SARS-CoV-2 nucleocapsid protein.

Huang W, Ju X, Tian M, Li X, Yu Y, Sun Q, Ding Q, Jia D. Huang W, et al. Among authors: yu y. Cell Discov. 2021 Aug 17;7(1):69. doi: 10.1038/s41421-021-00306-w. Cell Discov. 2021. PMID: 34400613 Free PMC article. No abstract available.

3

Mutation Y453F in the spike protein of SARS-CoV-2 enhances interaction with the mink ACE2 receptor for host adaption.

Ren W, Lan J, Ju X, Gong M, Long Q, Zhu Z, Yu Y, Wu J, Zhong J, Zhang R, Fan S, Zhong G, Huang A, Wang X, Ding Q. Ren W, et al. Among authors: yu y. PLoS Pathog. 2021 Nov 8;17(11):e1010053. doi: 10.1371/journal.ppat.1010053. eCollection 2021 Nov. PLoS Pathog. 2021. PMID: 34748603 Free PMC article.

4

A Nucleocapsid-based Transcomplementation Cell Culture System of SARS-CoV-2 to Recapitulate the Complete Viral Life Cycle.

Yu Y, Ju X, Ding Q. Yu Y, et al. Bio Protoc. 2021 Nov 5;11(21):e4257. doi: 10.21769/BioProtoc.4257. eCollection 2021 Nov 5. Bio Protoc. 2021. PMID: 34859136 Free PMC article.

5

An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.

Chi X, Zhang X, Pan S, Yu Y, Shi Y, Lin T, Duan H, Liu X, Chen W, Yang X, Chen L, Dong X, Ren L, Ding Q, Wang J, Yang W. Chi X, et al. Among authors: yu y. Signal Transduct Target Ther. 2022 Feb 9;7(1):44. doi: 10.1038/s41392-022-00912-4. Signal Transduct Target Ther. 2022. PMID: 35140196 Free PMC article.

6

Identified human breast milk compositions effectively inhibit SARS-CoV-2 and variants infection and replication.

Lai X, Yu Y, Xian W, Ye F, Ju X, Luo Y, Dong H, Zhou YH, Tan W, Zhuang H, Li T, Liu X, Ding Q, Xiang K. Lai X, et al. Among authors: yu y. iScience. 2022 Apr 15;25(4):104136. doi: 10.1016/j.isci.2022.104136. Epub 2022 Mar 22. iScience. 2022. PMID: 35342878 Free PMC article.

7

Design and characterization of novel SARS-CoV-2 fusion inhibitors with N-terminally extended HR2 peptides.

Hu Y, Zhu Y, Yu Y, Liu N, Ju X, Ding Q, He Y. Hu Y, et al. Among authors: yu y. Antiviral Res. 2023 Apr;212:105571. doi: 10.1016/j.antiviral.2023.105571. Epub 2023 Mar 1. Antiviral Res. 2023. PMID: 36868315 Free PMC article.

8

SARS-CoV-2 NSP8 suppresses type I and III IFN responses by modulating the RIG-I/MDA5, TRIF, and STING signaling pathways.

Deng J, Zheng SN, Xiao Y, Nan ML, Zhang J, Han L, Zheng Y, Yu Y, Ding Q, Gao C, Wang PH. Deng J, et al. Among authors: yu y. J Med Virol. 2023 Apr;95(4):e28680. doi: 10.1002/jmv.28680. J Med Virol. 2023. PMID: 36929724

9

A tissue specific-infection mouse model of SARS-CoV-2.

Yang B, Liu C, Ju X, Wu B, Wang Z, Dong F, Yu Y, Hou X, Fang M, Gao F, Guo X, Gui Y, Ding Q, Li W. Yang B, et al. Among authors: yu y. Cell Discov. 2023 Apr 20;9(1):43. doi: 10.1038/s41421-023-00536-0. Cell Discov. 2023. PMID: 37080957 Free PMC article.

10

The PRMT5/WDR77 complex restricts hepatitis E virus replication.

Ju X, Yu Y, Ren W, Dong L, Meng X, Deng H, Nan Y, Ding Q. Ju X, et al. Among authors: yu y. PLoS Pathog. 2023 Jun 5;19(6):e1011434. doi: 10.1371/journal.ppat.1011434. eCollection 2023 Jun. PLoS Pathog. 2023. PMID: 37276230 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

41,147 results

Search Page

Filters